Sign in
INVA Stock Price, Chart, Stats & News
Innoviva, Inc.
Save
1.65B
Market cap
3.57x
Current P/E
11.12x
Forward P/E
INVA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 78.87% |
Operating margin | -4.01% |
Pretax margin | 78.81% |
Net margin | 65.38% |
Effective tax rate | 17.04% |
ROA | 16.58% |
ROE | 30.60% |
D/E | 0.23x |
Interest coverage ratio | -0.99x |
INVA valuation
P/E | 3.57x |
P/S | 3.51x |
P/B | 1.45x |
P/CF | 8.61x |
P/FCF | 7.49x |
P/OCF | 8.61x |
PEG | 0.06x |
EV multiple | 4.66x |
About
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP.
Similar securities
Based on sector and market capitalization
Report issue